A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

As immunotherapy becomes a cornerstone of cancer treatment, some of the top U.S. cancer centers and health systems are accelerating research efforts to identify the biological mechanisms behind ...

According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...

Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Basel, Switzerland-based Roche recently launched the global cancer immunotherapy Centers of Research Excellence network. The imCORE network will unite scientific and clinical experts in cancer ...

This schematic illustrates stratification of gastrointestinal tract cancers based on their sensitivity to immunotherapy, thereby dictating distinct therapeutic paradigms that guide clinical ...

Cancer is the second-leading cause of death in the United States, accounting for over 613,000 fatalities in 2023, per the Centers for Disease Control. But the field of cancer vaccines, which can be ...